Navamedic ASA: Q4 2021 financial results
Oslo, 17 February 2022 - Navamedic ASA (OSE: NAVA) grew revenues by 63% in the fourth quarter of 2021 compared to the same quarter last year. The company reported revenues of NOK 90.2 million in the fourth quarter of 2021 with an EBITDA of NOK 7.6 million, driven by underlying growth in the portfolio and Mysimba® in particular. The company reiterates its mid-term ambition of building a NOK 500 million company through organic growth.“The fourth quarter of 2021 was strong for Navamedic, resulting in a full year growth of 33%, compared to our targeted growth rate of 20%. We have seen an